HUTCHMED (CHINA) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 352 GBX | +4.14% |
|
+13.55% | +24.38% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,356 | 4,555 | 6,141 | 2,698 | 3,074 | 3,760 | - | - |
| Enterprise Value (EV) 1 | 3,165 | 4,147 | 5,156 | 2,085 | 2,870 | 3,562 | 3,455 | 3,549 |
| P/E ratio | -31.5 x | -34.9 x | -28.7 x | -7.43 x | 30 x | -32.5 x | 684 x | 38.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 16.4 x | 20 x | 17.2 x | 6.33 x | 3.67 x | 5.48 x | 4.46 x | 3.64 x |
| EV / Revenue | 15.4 x | 18.2 x | 14.5 x | 4.89 x | 3.42 x | 5.19 x | 4.1 x | 3.44 x |
| EV / EBITDA | -22.4 x | -21.8 x | -16.1 x | -5.23 x | 108 x | -23.9 x | -67.8 x | 159 x |
| EV / FCF | -35.4 x | - | -23.4 x | -6.83 x | 15.4 x | -18 x | -82 x | 81.1 x |
| FCF Yield | -2.83% | - | -4.28% | -14.6% | 6.5% | -5.54% | -1.22% | 1.23% |
| Price to Book | 11.7 x | 9.46 x | 6.28 x | 4.52 x | 4.29 x | 1.91 x | 1.87 x | 1.54 x |
| Nbr of stocks (in thousands) | 665,965 | 724,205 | 856,470 | 845,074 | 853,410 | 853,644 | - | - |
| Reference price 2 | 5.039 | 6.290 | 7.170 | 3.193 | 3.602 | 4.405 | 4.405 | 4.405 |
| Announcement Date | 3/3/20 | 3/4/21 | 3/3/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 204.9 | 228 | 356.1 | 426.4 | 838 | 686.1 | 842.4 | 1,032 |
| EBITDA 1 | -141.4 | -190.6 | -321.1 | -399 | 26.58 | -149 | -50.95 | 22.28 |
| EBIT 1 | -146.4 | -196.7 | -328.3 | -407.7 | 18.38 | -151.2 | -59.83 | 36.6 |
| Operating Margin | -71.45% | -86.27% | -92.19% | -95.61% | 2.19% | -22.04% | -7.1% | 3.55% |
| Earnings before Tax (EBT) 1 | -141.1 | -189.7 | -215.7 | -410.4 | 58.31 | -139.7 | -29.53 | 62.56 |
| Net income 1 | -106 | -125.7 | -194.6 | -360.8 | 100.8 | -106.6 | -2.099 | 92.17 |
| Net margin | -51.75% | -55.15% | -54.66% | -84.62% | 12.03% | -15.54% | -0.25% | 8.93% |
| EPS 2 | -0.1600 | -0.1800 | -0.2500 | -0.4300 | 0.1200 | -0.1355 | 0.006440 | 0.1137 |
| Free Cash Flow 1 | -89.48 | - | -220.6 | -305.3 | 186.6 | -197.4 | -42.12 | 43.73 |
| FCF margin | -43.67% | - | -61.95% | -71.59% | 22.27% | -28.78% | -5% | 4.24% |
| FCF Conversion (EBITDA) | - | - | - | - | 702.15% | - | - | 196.32% |
| FCF Conversion (Net income) | - | - | - | - | 185.2% | - | - | 47.45% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 3/4/21 | 3/3/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 102.7 | 106.8 | 121.2 | 157.4 | 198.8 | 202 | 224.4 | 532.9 | 305.1 | 321.9 | 349.3 | 404.9 | 414.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -78.16 | -118.5 | -143.7 | -184.6 | -196.8 | -210.9 | 111.7 | -93.28 | -65.2 | -79.6 | -61.44 | -67.52 |
| Operating Margin | - | -73.21% | -97.77% | -91.34% | -92.86% | -97.38% | -94.02% | 20.95% | -30.57% | -20.25% | -22.79% | -15.18% | -16.28% |
| Earnings before Tax (EBT) 1 | - | -76.58 | -113.2 | -140.4 | -75.29 | -200.6 | -209.8 | - | -78.78 | -39.7 | -103.1 | - | - |
| Net income 1 | - | -49.69 | -76.04 | -102.4 | -92.25 | -162.9 | -198 | - | -67.77 | -52.6 | -64.3 | - | - |
| Net margin | - | -46.55% | -62.73% | -65.07% | -46.41% | -80.61% | -88.24% | - | -22.21% | -16.34% | -18.41% | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 7/30/20 | 3/4/21 | 7/28/21 | 3/3/22 | 8/1/22 | 2/28/23 | 7/31/23 | 2/28/24 | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 190 | 408 | 985 | 613 | 204 | 199 | 306 | 212 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -89.5 | - | -221 | -305 | 187 | -197 | -42.1 | 43.7 |
| ROE (net income / shareholders' equity) | -31.3% | -32.6% | -26.5% | -45.2% | 13.8% | -12.8% | -1.6% | 11.1% |
| ROA (Net income/ Total Assets) | -21.3% | -21.1% | -18.6% | -30% | 7.88% | -9.15% | -2.52% | 5.09% |
| Assets 1 | 498.6 | 594.6 | 1,048 | 1,201 | 1,280 | 1,165 | 83.29 | 1,812 |
| Book Value Per Share 2 | 0.4300 | 0.6700 | 1.140 | 0.7100 | 0.8400 | 2.310 | 2.350 | 2.860 |
| Cash Flow per Share 2 | -0.1200 | -0.0900 | -0.2600 | -0.3200 | 0.2500 | -0.1300 | -0.0300 | 0.0900 |
| Capex 1 | 8.57 | 7.95 | 16.4 | 36.7 | 32.6 | 28 | 23.7 | 27.1 |
| Capex / Sales | 4.18% | 3.49% | 4.61% | 8.6% | 3.89% | 4.09% | 2.81% | 2.62% |
| Announcement Date | 3/3/20 | 3/4/21 | 3/3/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.405
USD
Average target price
5.386
USD
Spread / Average Target
+22.26%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.38% | 3.76B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- HCM Stock
- Financials HUTCHMED (China) Limited
